Introduction
Type 1 diabetes (T1DM) is one of the organ-specific autoimmune diseases, characterized by the T-cell mediated destruction of insulin-producing beta-cells in the pancreas. 1 It is considered that various environmental and genetic factors and various genes are involved in the development of the disease. A major candidate gene for T1DM is HLA class II gene located in IDDM1 locus, accounting for about 50% of T1DM genetic risk. 2 Wholegenome searches have identified at least 18 T1DM susceptibility loci in humans. [2] [3] [4] [5] Recently, novel genome T1DM scans have been reported. 6, 7 Inbred non-obese diabetic (NOD) mice, an experimental model for human T1DM, spontaneously develop an autoimmune diabetes. 8, 9 It is now well accepted that autoreactive T cells, which infiltrate the islets, destroy insulin-producing beta-cells of NOD mice. Recently, Kurts et al 10 have reported that islet-specific CD8 + T cells in CD30 deficient mice markedly promoted the destruction of pancreatic cells and resulted in the rapid development of diabetes. These results suggested that CD30 signal transduction might protect against autoimmunity by preventing extensive expansion of autoreactive CD8 + effector T cells. In addition, signal transduction between CD30 and CD30L may play a role in the protection against autoimmune insulitis through the suppression of Th1-cytokine responses because an interaction between CD30 and CD30L was involved in Th2-responses. 11 Murine CD30 gene is mapped to the distal region of chromosome 4 containing the T1DM susceptibility locus Idd9.2, and various sequence differences between NOD and diabetes-resistant strains in both coding and noncoding regions of the CD30 gene were reported. [12] [13] [14] It is possible that variants within CD30 may alter its function, thereby generating a more vigorous immune response to infection as well as to autoantigens. This observation suggests that CD30 gene is a good candidate gene for T1DM in humans as well as in mice. Murine CD30L gene is mapped to the distal region of chromosome 4 not including NOD susceptibility locus, and human CD30L gene on chromosome 9q33 is not within T1DM susceptibility loci. 15 However, chromosome 9q33 includes one of the susceptibility loci of asthma, a characteristic disease of Th1/Th2 imbalance in human 16 and, hence CD30L gene may also contribute to the pathogenesis of T1DM in combination with the genetic background of CD30 gene. These findings promoted us to explore the significance of CD30 and CD30L genes in the predisposition to T1DM. We first screened for polymorphisms in CD30 and CD30L genes and investigated an association of CD30 or CD30L gene polymorphisms with T1DM in the Japanese population.
Results
Searching for polymorphisms in the CD30L and CD30 genes Direct-sequencing of the coding region of the CD30L gene in 20 healthy individuals showed three polymorphisms: a microsatellite (CA)n repeat polymorphism in the promoter region (around −200 bp from the transcription start site); a G and A dimorphism at the nucleotide position 276 (calculated from the first ATG, third nucleotide of codon 92) in exon 3, which creates no amino acid change; and a T and C dimorphism at −73 in the intron 3. These three polymorphisms were under a linkage disequilibrium (Table 1) .
Regarding the promoter region of CD30 gene, a novel 2 analysis with a 2 × 2 contingency table. Bonferroni multiple adjustment was made to the level of significance, which was set at P-value Ͻ 0.0083. The whole allele distributions between patients and controls were compared by means of 2 analysis with a 2 × 6 contingency table. OR = odds ratio; 95% CI = 95% confidence interval.
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G and A dimorphism was identified at the nucleotide position of −201 from the transcription start site. We were unable to detect any polymorphisms by the screening of the 5Ј UTR or coding region of CD30 gene.
Allele and genotype frequencies of CD30L promoter (CA)n, exon 3 276G/A, and IVS3 −73T/C polymorphisms As for the CD30L promoter (CA)n repeat polymorphism, six discrete alleles were identified in the Japanese population with sizes ranging from 186 to 196 bp, corresponding to (CA) 9 to (CA) 14 repeats. There was no significant difference in the allele frequencies of this polymorphism between T1DM patients and controls ( Table 2 ). The G:A allele frequencies of 276G/A and T:C allele frequencies of intron 3 −73T/C polymorphisms in CD30L gene were estimated to be 0.64:0.36 and 0.54:0.46 from 200 Japanese healthy subjects, respectively. No significant differences were observed in the allele and genotype frequencies of these dimorphism between T1DM patients and controls (Table 3 ). When we subdivided the whole population into males and females, the frequency of (CA) 9 allele was slightly higher in female patients with T1DM than that in female controls (P = 0.03) ( Table 2 ). With respect of IVS3 −73T/C polymorphism, the frequency of T allele was also higher in T1DM female patients than that in female control subjects (64.6% vs 53.9%, respectively, P = 0.03) ( Table 4 ).
Allele and genotype frequencies of CD30 −201G/A
The G:A allele frequencies of −201G/A polymorphism in CD30 gene were estimated to be 0.95:0.05. No significant differences were observed in the allele and genotype frequencies of this polymorphism between T1DM patients and controls (Table 3) . No associations were observed after subdivision of the patients according to gender or age at onset (Table 4) . 
Discussion
CD30 is a member of the TNF receptor family, and exclusively interacts with CD30L. CD30 and CD30L molecules may play a role in the protection against autoimmune insulitis through the suppression of Th1 cytokine responses and islet-specific T cells. 10 In the present study, four new polymorphisms in CD30 and CD30L genes were identified. Among them, −201 G/A in CD30 and (CA)n repeat polymorphism in CD30L are located within the promoter regions but not on the direct DNA-binding site of the genes and create no new binding motifs for known transcription factors. In fact, we were unable to find a significant association between these polymorphisms and T1DM in the whole population, however, further analysis with more samples should be needed for a final conclusion, since a frequency of A allele of CD30 −201 G/A polymorphism was relatively low. In addition, there was a slight difference in the allele frequencies of the (CA)n repeat of CD30L gene between patients and controls in the female population, suggesting a possibility that the sequence variation of (CA)n repeat in CD30L promoter influences the transcriptional regulation of CD30L gene expression. The association study between IVS3 −73T/C polymorphism of CD30L gene and T1DM showed a similar result as that of (CA)n repeat of CD30L. As the IVS3 −73T/C polymorphism locates in the intron, it is less likely that this polymorphism directly alters the function of CD30L gene, but it may work through a possible functional polymorphism of (CA)n repeat in the promoter region under a linkage disequilibrium. Alternatively, undetermined polymorphisms with functional significance around CD30L gene may influence the present results. Recently, the genomic sequence of human CD30 gene has been registered in GenBank Database (accession number AJ289159). We pre- One-base mismatch was introduced at the 3Ј end of this primer (shown by the underline). The nucleotide data reported in this paper will appear in the GenBank nucleotide sequence databases with the accession numbers AF006381, AF006382.1, AF006383 and AF006384 for CD30L gene; AF065475 and M83554 for CD30 gene.
liminary compared the human CD30 genes of the genomic sequence with that of mRNA (accession number M83554), and found a candidate polymorphic site at the nucleotide position of 1204A/G (Ser402Gly). However, since we did not find this polymorphism by the directsequencing of CD30 cDNA from 20 alleles from normal individuals in this study, this polymorphism, even if it exists in the Japanese population, may be too low in frequency to be significant.
A possible explanation for the present data that CD30L gene was associated with the development of T1DM only in the female population might include the difference in the susceptible genes between males and females as reported in NOD mice. [17] [18] [19] As progesterone, one of the major female sex hormones, induced membrane CD30 Genes and Immunity expression on Th1-like clones, 20 it was suggested that certain hormones and possible functional polymorphisms in the CD30L gene may have a synergistic effect on the development of T1DM in the Japanese female population.
It is likely that susceptibility genes for T1DM in Japanese are different from the Caucasian population in European countries, because there is a great difference in the incidence of T1DM between two populations. 21 Further study is important to evaluate a contribution of CD30/CD30L gene polymorphisms with T1DM in other ethnic groups. Additionally, since the CD30/CD30L pathway may play important roles in autoimmunity, analysis of the identified polymorphisms in other autoimmune diseases may give us important information for the understanding of autoimmune diseases. 
Subjects and methods

Subjects
The study population consisted of 155 unrelated Japanese patients with T1DM (96 females and 59 males) and 200 unrelated Japanese healthy individuals (103 females and 97 males). This study population comprise only Japanese people, excluding minor distinct ethnic groups (Ainu in Hokkaido and Ryukyu in Okinawa), and immigrants from Korea and China. All T1DM patients were diagnosed by endocrinologists according to the criteria of National Diabetes Data Group. 22 The median age at the onset was 7.4 ± 4.2 years, ranging from 0 to 16 years. Healthy individuals consisted of school children, around 10 years of age. Informed consent was obtained from subjects and/or their parents.
DNA extraction
Genomic DNA was obtained from peripheral blood lymphocytes using the QIAamp DNA extraction kit (Qiagen, Tokyo, Japan). 
Direct-sequencing analysis of CD30L and CD30 genes
The entire protein-coding region of the CD30L gene consists of four exons. Since a part of promotor and 5Ј UTR of CD30 gene was only available from GenBank database, the genomic sequence from −350 to +204 bp was chosen for the amplification. To amplify these regions, we constructed five sets of polymerase chain reaction (PCR) primers and screened for polymorphisms in 20 healthy individuals. Amplifications were performed using 20 ng of genomic DNA, 25 pmol of each primer, 1.25 unit of Taq polymerase (Promega, Madison, WI, USA) and 0.2 mM of each deoxynucleotide triphosphate in 50 l reaction. A whole coding region with a part of the 5Ј UTR (around 200 bp upstream of the translational initiation ATG) of the CD30 gene was amplified by nested PCR method from RNA samples. Total RNA was isolated from peripheral blood lymphocytes from 10 T1DM patients using ISOGEN-LS (NIPPON GENE, Osaka, Japan). cDNA was synthesized by the First-Strand cDNA synthesis kit (Amersham Pharmacia Biotech, Uppsala, Sweden). First round PCR amplification was performed by synthesized cDNA. In the second round PCR amplification, the whole coding region was divided into four segments. The second-round PCR was carried out with the first PCR product as a template. The sequences of primers and PCR thermal conditions are shown in Tables  5 and 6 . The amplified products were purified by the QIAquick PCR purification kit (Qiagen, Tokyo, Japan), and the direct-sequencing was carried out with fluorescent dideoxy-terminator method by an ABI PRISM 310 genetic analyzer (Perkin-Elmer, Foster City, CA, USA).
Restriction fragment length polymorphism (RFLP)
analysis of CD30L gene exon 3 276G/A and IVS3 −73T/C polymorphisms The genotypes of the 276G/A and the −73T/C polymorphisms were analyzed by PCR amplification followed by RFLP. The sequences of primers and PCR thermal conditions are present in Tables 5 and 6 . The amplified products were incubated at 37°C for 1 h with Sac I and Bcl I restriction enzymes, respectively, separated on 3.0% agarose gels and visualized with ethidium bromide staining (Figures 1a and 1b) .
Genotyping of (CA)n repeat polymorphism in the promoter region of CD30L gene PCR with a fluorescence-labeled primer was performed for genotyping the polymorphic (CA)n repeat in the promoter region of CD30L gene. The 5Ј end of the forward primer was labeled with 6-carboxyfluorescein (6-FAM) dye. The sequences of primers and PCR thermal conditions are shown in Tables 5 and 6 . Genotyping was performed in a mixture of amplified products and an internal size standard by an ABI PRISM 310 genetic analyzer. Tables 5 and 6 .
Evaluation of linkage disequilibrium
Linkage disequilibrium was calculated in the T1DM and control populations independently according to the method as reported by Mittal. 23 A value calculated by ⌬/s.e. greater than +2 or lesser than −2 indicated a significant positive or negative linkage disequilibrium, respectively.
Statistical analysis
Differences in the allele and genotype frequencies of CD30 gene −201G/A, CD30L gene 276G/A and IVS3 −73T/C, between patients and controls were evaluated by 2 analysis with 2 × 2 and 2 × 3 contingency tables. When at least one cell number was not more than 5, Yates' correction was applied for the 2 value. A P-value Ͻ0.05 was considered to be statistically significant. The distribution of each allele of the CD30L promoter (CA)n in patients was compared with those in controls using a chi-square test for a 2 × 2 contingency table. Because of the multiple comparisons for the microsatellite allele frequencies, a Bonferroni multiple adjustment was made to the level of significance, which was set at P-value Ͻ0.0083 (0.05/6). Comparison of whole allele distribution between patients and controls was performed using a 2 test for a 2 × 6 contingency table with a significance level P Ͻ 0.05.
